61
Participants
Start Date
February 13, 2023
Primary Completion Date
December 31, 2024
Study Completion Date
December 31, 2024
tazemetostat
"Dose Escalation Phase (Phase IIa):~Tazemetostat (800 mg BID orally) in a therapeutic cycle of 28 days;~Dose Expansion Phase (Phase IIb):~Tazemetostat (800 mg BID orally) in a therapeutic cycle of 28 days"
HMPL-689
"Dose Escalation Phase (Phase IIa):~HMPL-689:20 mg and 30 mg, QD orally in a therapeutic cycle of 28 days.~Dose Expansion Phase (Phase IIb):~HMPL-689 (RP2D) in a therapeutic cycle of 28 days"
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai
Lead Sponsor
Hutchmed
INDUSTRY